A Study of Combination of Temsirolimus (Torisel®) and Pegylated Liposomal Doxorubicin (PLD, Doxil®/Caelyx®) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Advanced/Recurrent Breast Cancer|Endometrial Cancer|Ovarian Cancer
Interventions: DRUG: Temsirolimus/PLD
Sponsor: Radboud University Medical Center